Kehua Bio-Engineering reports Q3 net loss amid restructuring and new product

Shanghai Kehua Bio-Engineering reported a net loss attributable to shareholders of CNY -99,080,102.24 in Q3 2025, widening to CNY -232,532,785.65 for the year-to-date. This reflects a significant decline from the previous year and comes as the company announces a strategic restructuring, with Ms. Jin Hongying resigning as a non-independent director. Mr. Yi Chao has been elected as a new employee representative director.

Operationally, the company received a medical device registration certificate for an automatic nucleic acid detection and analysis instrument, expanding its product line. Furthermore, the board approved a plan to manage idle self-owned funds up to CNY 500 million for cash management purposes, investing in low-risk, highly liquid financial products to optimize capital efficiency. Shareholder resolutions include revisions to the company’s articles of association and internal management systems.

The company also announced that its "Kehua Convertible Bonds" met conditions for conditional put-back, leading to a valid put-back application for 70 bonds totaling CNY 7,016.87.